Integrative Analysis of CRC Liver Metastasis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: normal colorectal tissues.
- Who it may be relevant to
- Registry conditions: Metastasis. Basic parameters: 18 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The investigators will perform integrative analysis of CRC liver metastasis
Detailed description
The investigators will analyzed proteomes of paired normal colorectal tissues and colorectal cancer (CRC) with or without liver metastasis, sequenced transcriptomes, performed whole exome sequencing, and single nucleotide polymorphism (SNP) array profiling for triplets, each comprising normal colorectal tissue, primary colorectal carcinoma, and its synchronous matched liver metastasis, as well as analyzed genomics of CRC characterized previously by The Cancer Genome Atlas (TCGA) to conduct integrated proteogenomic analyses.
Interventions
- Other normal colorectal tissues
The investigators will extract total protein, DNA and RNA from these groups.
Primary outcome measures
- 5 years overall survival [Time frame: 5 years]
Secondary outcome measures (1)
- 5 years disease-free survival [Time frame: 5 years]
Eligibility criteria
Inclusion criteria
- Age ≤ 75 years with histologically proven CRC
- No severe major organ dysfunction
- WHO performance status of 0 or 1
- No prior cancer chemotherapy
Exclusion criteria
- Age ≥ 76
- Severe major organ dysfunction
- World Health Organization (WHO) performance status of >1
- Prior cancer chemotherapy
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-control
Study locations
China · 2 centers
- Ganzhou City People's Hospital — Ganzhou
- Shanghai Tenth People's Hospital — Shanghai
Publications
- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4. PMID 25651787
- Ma YS, Huang T, Zhong XM, Zhang HW, Cong XL, Xu H, Lu GX, Yu F, Xue SB, Lv ZW, Fu D. Proteogenomic characterization and comprehensive integrative genomic analysis of human colorectal cancer liver metastasis. Mol Cancer. 2018 Sep 21;17(1):139. doi: 10.1186/s12943-018-0890-1. PMID 30241526
Identifiers
NCT: NCT02917707 · Y219J11311